Hutter R V
Cancer. 1984 Feb 1;53(3 Suppl):798-802. doi: 10.1002/1097-0142(19840201)53:3+<798::aid-cncr2820531331>3.0.co;2-p.
The management of patients with lobular carcinoma in situ (LCIS) has been an enigma for almost as long as the entity has been known. Continued follow-up of these patients has documented that about a quarter to a third will subsequently develop carcinoma in either breast after diagnostic excision, but no further therapy. Lobular carcinoma in situ has a 60% to 90% rate of multicentricity, and about 4% to 6% of mastectomy specimens from patients with LCIS have an invasive cancer elsewhere in the breast. Furthermore, 20% to 45% of women with LCIS have synchronous, or develop metachronous, contralateral breast cancer. The management programs range from clinical follow-up to bilateral mastectomy with reconstruction. These and various other choices are discussed. Since there is no conclusive evidence to justify the selection of any single program to the exclusion of all others, the informed patient must select from among the choices that program which will best satisfy her medical as well as psychosocial needs.
小叶原位癌（LCIS）患者的管理几乎自该疾病被发现以来就一直是个谜。对这些患者的持续随访记录显示，在诊断性切除后，约四分之一至三分之一的患者随后会在双侧乳房中发生癌变，但无需进一步治疗。小叶原位癌具有60%至90%的多中心发生率，并且在接受LCIS治疗的患者中，约4%至6%的乳房切除术标本在乳房其他部位存在浸润性癌。此外，20%至45%的LCIS女性患有同步或异时性对侧乳腺癌。管理方案从临床随访到双侧乳房切除并重建不等。本文将讨论这些以及其他各种选择。由于没有确凿证据支持选择任何单一方案而排除其他所有方案，明智的患者必须从这些选择中挑选出最能满足其医疗和心理社会需求的方案。
